OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 6,002 GILD derivative securities | OQRO

Home
Insider trades
Gilead Sciences
Officer exercised or converted 6,002 GILD derivative securities

Insider trades

Insider trade

Officer exercised or converted 6,002 GILD derivative securities

Traded Aug 10, 2026 · Filed Aug 11, 2026

GILGilead SciencesGILD

6,002
Shares

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 10, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 11, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0002110603-26-000010

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Aug 11, 2026, 8:51 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Wettan Keeley M Cain

Relationship

Officer

Officer title

EVP Gen Counsel, Legal & Comp

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Aug 10, 2026

Transaction code

Shares / units

6,002

Acquired / disposed

Acquired (A)

Shares owned after

11,362

Ownership form

Direct

Amendment

Footnotes from the filing

Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

Around the same time

CEO sold ~$236K of Gilead Sciences

Scheduled in advance5w ago

CEO sold ~$1.19M of Gilead Sciences

Scheduled in advance5w ago

CEO sold ~$808K of Gilead Sciences

Scheduled in advance5w ago